The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Discuss recent FDA approvals and practice guideline updates related to advancing care for patients with metastatic
HER2-overexpressing breast cancer.
Interpret the increased clinical relevance of the new "HER2-low" category of HER2 expression for the treatment of patients with metastatic breast cancer.
Apply evidence-based best practices when monitoring and managing adverse events associated with novel HER2-targeted agents when caring for patients with metastatic breast cancer.
Speaker(s):
Stephanie
L. Graff,
Associate ProfessorDirector of Breast Oncology,
Legoretta Cancer Center at Brown UniversityLifespan Cancer Institute